FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997685722> ?p ?o ?g. }

• W1997685722 endingPage "798" @default.
• W1997685722 startingPage "790" @default.
• W1997685722 abstract "Recombinant factor VIIa (rFVIIa) was developed to provide an improved procoagulant component capable of 'by-passing' inhibitor antibodies in the treatment of haemophilic patients. The primary objective of this study was to compare the efficacy of two dosage regimens of rFVIIa (given intravenously at periodic intervals) in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B with and without inhibitors. The study was designed as a randomized, double-blind, parallel group, international multicenter trial. Patients were randomly allocated to treatment A: 35 mu kg-1 or B: 70 mu kg-1, in blocks of 2. Within each block, one patient was assigned to the 35 mu kg-1 dosing regimen and the other to 70 mu kg-1 dose. One hundred and fifty subjects from 20 sites were screened for this study and 116 had baseline assessments. Of these, 84 were treated on the protocol and 32 were not treated in the study, in most cases because they did not return to the clinic with an eligible bleeding episode. One hundred and seventy-nine bleeding episodes were treated, of which 145 (81%) were acute haemarthroses. Both treatments were efficacious, with 71% having an excellent (59% and 60%) or effective (12% and 11%) response. Overall, the mean and median number of doses given per episode of joint bleeding were 3.1 and 2, respectively. The mean number of doses was 3.1 for the 70 mu kg-1 group and 2.7 for the 35 mu kg-1 group (P value = 0.142). The study concluded that rFVIIa in a dosage of 35 mu kg-1 or 70 mu kg-1 is both safe and reasonably effective in the treatment of joint or muscle haemorrhages in haemophilic patients with inhibitor antibodies to factor VIII or factor IX. It is concluded that the appropriate dose for the treatment of joint and peripheral muscle bleeding in haemophilic patients with inhibitors is 35-70 mu kg-1 given at 2-3 h intervals until haemostasis is achieved." @default.
• W1997685722 created "2016-06-24" @default.
• W1997685722 creator A5007308061 @default.
• W1997685722 creator A5013059770 @default.
• W1997685722 creator A5031967524 @default.
• W1997685722 creator A5038597185 @default.
• W1997685722 creator A5051512955 @default.
• W1997685722 creator A5065489740 @default.
• W1997685722 creator A5074574903 @default.
• W1997685722 creator A5086624133 @default.
• W1997685722 creator A5088954638 @default.
• W1997685722 date "1998-11-01" @default.
• W1997685722 modified "2023-09-25" @default.
• W1997685722 title "A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors" @default.
• W1997685722 cites W1551842960 @default.
• W1997685722 cites W1982671659 @default.
• W1997685722 cites W1989174872 @default.
• W1997685722 cites W1992829986 @default.
• W1997685722 cites W1996513809 @default.
• W1997685722 cites W2017164294 @default.
• W1997685722 cites W2037721115 @default.
• W1997685722 cites W2042508808 @default.
• W1997685722 cites W2050510640 @default.
• W1997685722 cites W2052329983 @default.
• W1997685722 cites W2069315692 @default.
• W1997685722 cites W2088684447 @default.
• W1997685722 cites W2321411638 @default.
• W1997685722 cites W2324395680 @default.
• W1997685722 cites W2337290468 @default.
• W1997685722 cites W2396194974 @default.
• W1997685722 cites W2403444710 @default.
• W1997685722 cites W2416168099 @default.
• W1997685722 cites W2422227088 @default.
• W1997685722 cites W2734698134 @default.
• W1997685722 doi "https://doi.org/10.1046/j.1365-2516.1998.00209.x" @default.
• W1997685722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10028299" @default.
• W1997685722 hasPublicationYear "1998" @default.
• W1997685722 type Work @default.
• W1997685722 sameAs 1997685722 @default.
• W1997685722 citedByCount "201" @default.
• W1997685722 countsByYear W19976857222012 @default.
• W1997685722 countsByYear W19976857222013 @default.
• W1997685722 countsByYear W19976857222014 @default.
• W1997685722 countsByYear W19976857222015 @default.
• W1997685722 countsByYear W19976857222016 @default.
• W1997685722 countsByYear W19976857222017 @default.
• W1997685722 countsByYear W19976857222018 @default.
• W1997685722 countsByYear W19976857222019 @default.
• W1997685722 countsByYear W19976857222020 @default.
• W1997685722 countsByYear W19976857222021 @default.
• W1997685722 countsByYear W19976857222022 @default.
• W1997685722 countsByYear W19976857222023 @default.
• W1997685722 crossrefType "journal-article" @default.
• W1997685722 hasAuthorship W1997685722A5007308061 @default.
• W1997685722 hasAuthorship W1997685722A5013059770 @default.
• W1997685722 hasAuthorship W1997685722A5031967524 @default.
• W1997685722 hasAuthorship W1997685722A5038597185 @default.
• W1997685722 hasAuthorship W1997685722A5051512955 @default.
• W1997685722 hasAuthorship W1997685722A5065489740 @default.
• W1997685722 hasAuthorship W1997685722A5074574903 @default.
• W1997685722 hasAuthorship W1997685722A5086624133 @default.
• W1997685722 hasAuthorship W1997685722A5088954638 @default.
• W1997685722 hasConcept C126322002 @default.
• W1997685722 hasConcept C141071460 @default.
• W1997685722 hasConcept C156662089 @default.
• W1997685722 hasConcept C168563851 @default.
• W1997685722 hasConcept C204243189 @default.
• W1997685722 hasConcept C2777232031 @default.
• W1997685722 hasConcept C2777288759 @default.
• W1997685722 hasConcept C2777785397 @default.
• W1997685722 hasConcept C2778385053 @default.
• W1997685722 hasConcept C2778961111 @default.
• W1997685722 hasConcept C2779134260 @default.
• W1997685722 hasConcept C2779526002 @default.
• W1997685722 hasConcept C2781413609 @default.
• W1997685722 hasConcept C71924100 @default.
• W1997685722 hasConcept C90924648 @default.
• W1997685722 hasConceptScore W1997685722C126322002 @default.
• W1997685722 hasConceptScore W1997685722C141071460 @default.
• W1997685722 hasConceptScore W1997685722C156662089 @default.
• W1997685722 hasConceptScore W1997685722C168563851 @default.
• W1997685722 hasConceptScore W1997685722C204243189 @default.
• W1997685722 hasConceptScore W1997685722C2777232031 @default.
• W1997685722 hasConceptScore W1997685722C2777288759 @default.
• W1997685722 hasConceptScore W1997685722C2777785397 @default.
• W1997685722 hasConceptScore W1997685722C2778385053 @default.
• W1997685722 hasConceptScore W1997685722C2778961111 @default.
• W1997685722 hasConceptScore W1997685722C2779134260 @default.
• W1997685722 hasConceptScore W1997685722C2779526002 @default.
• W1997685722 hasConceptScore W1997685722C2781413609 @default.
• W1997685722 hasConceptScore W1997685722C71924100 @default.
• W1997685722 hasConceptScore W1997685722C90924648 @default.
• W1997685722 hasIssue "6" @default.
• W1997685722 hasLocation W19976857221 @default.
• W1997685722 hasLocation W19976857222 @default.
• W1997685722 hasOpenAccess W1997685722 @default.
• W1997685722 hasPrimaryLocation W19976857221 @default.
• W1997685722 hasRelatedWork W1985942326 @default.

• next